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Abstract (250 words) 
Objectives: Assessment of Raynaud’s phenomenon (RP) in systemic sclerosis (SSc) is 
reliant on self-report. The Raynaud’s Condition Score (RCS) diary assumes discrete episodic 
RP attacks, although not all SSc patients identify with this paradigm. We investigated the 
clinical associations of SSc-RP symptom characteristics and evolution of SSc-RP symptoms 
with disease progression.  
Methods: A cross-sectional study at UK and US sites captured digital colour changes of SSc-
RP and patient’s ability to identify with diagrammatic representations (and descriptive stems) 
of four distinct theoretical SSc-RP patterns (progressing severity through A-D) reflecting 
progressively severe SSc-RP experiences. SSc-RP self-management and symptom evolution 
were explored. Patient demographics, clinical phenotype, scleroderma Health Assessment 
Questionnaire (SHAQ), the 2-week RCS diary and patient and physician global assessments 
were collected.  
Results: We enrolled 107 SSc patients (questionnaires returned by 94).  A higher number of 
self-reported digital colour changes of SSc-RP were associated with increased SSc-RP 
symptom severity but not SSc clinical phenotype. Patients could identify with distinct 
patterns of SSc-RP. These patterns were associated with disease duration, global disease 
severity and conceptually-linked physician and patient assessments of peripheral vascular 
severity (e.g. SHAQ RP subscale and RCS diary parameters), but not conceptually unrelated 
outcomes (e.g. SHAQ Breathing subscale). SSc-RP characteristics and symptom severity 
evolve during the disease course. 
Conclusions: Patients identify with distinct patterns of SSc-RP that may relate to progression 
of the obliterative microangiopathy of SSc. Difficulty distinguishing discrete SSc-RP attacks 
from persistent digital ischaemia in advanced SSc could influence diary-based approaches to 
assessing SSc-RP with implications for clinical trials.  
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Significance and Innovation 
• Patients with SSc can identify with distinct patterns of RP symptoms that may 
reflect progression of the obliterative microangiopathy of SSc. 
• The evolution of RP symptom burden in SSc reflects a complex inter-relationship 
between progression of the peripheral vasculopathy and successful patient 
adaptation 
• RP symptom characteristics in SSc are not adequately reflected in existing 
outcome measures for assessing RP severity in clinical trials 
Key Words 
Raynaud’s phenomenon, systemic sclerosis, patient reported outcomes, outcome measures, 
clinical trials 
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Raynaud’s phenomenon (RP) is the term used to describe episodic excessive vasoconstriction 
of the digital microvasculature in response to cold exposure and/or emotional stress (1). RP is 
a major cause of disease-related morbidity in systemic sclerosis (SSc) (2-4). SSc-RP is 
associated with digital color changes reflecting the perfusion and oxygenation of affected 
tissues (1). The episodic nature of RP precludes useful assessment in the clinical setting and 
has led to a reliance on patient self-report. Classification (and diagnosis) of RP generally 
requires the presence of bi-phasic digital color changes (5-7).  The assessment of RP 
symptoms can be undertaken using self-reported patient questionnaires with or without the 
aid of colour charts demonstrating the appearances of the digits during RP attacks (7, 8). A 
previous study reported uni-phasic digital color changes of RP in over half of patients with 
SSc could have implications for disease classification (9). The relationship between specific 
digital color changes and clinical phenotype has not previously been explored but could 
provide a readily available tool in the clinical setting (3, 4).  Assessment of SSc-RP severity 
is also reliant on patient-reported outcome (PRO) instruments such as the Raynaud’s 
Condition Score (RCS) diary. The 2-week RCS diary collects information on the frequency, 
duration and severity/impact of SSc-RP attacks (10). SSc-RP attack frequency is frequently 
the primary endpoint in SSc-RP clinical trials (11, 12). The RCS diary assumes a paradigm of 
discrete attacks of SSc-RP in which patients are cognizant of the emergence and abatement of 
symptoms. Consistent with other clinician-derived PRO instruments developed at the time, 
there was no direct patient involvement in the development of the RCS diary (13). Recent 
work examining the patient experience of SSc-RP and patient perceptions of the RCS diary 
suggests patients conceptualize SSc-RP in a more nebulous fashion that incorporates both 
discrete exacerbations on a background of more persistent digital ischemia (4, 14). Indeed 
some patients report difficulty knowing what an “attack” of SSc-RP represents (4, 14). These 
experiences are consistent with the recognized progressive obliterative microangiopathy of 
SSc and might explain the poor agreement between RCS diary parameters and non-invasive 
Evolving symptoms of RP in SSc 
 
  6 
 
microvascular imaging assessments of digital microvascular function (15, 16). No previous 
studies have examined whether different patterns of RP exist in SSc, and whether RP 
symptoms evolve with disease progression. The Raynaud’s Symptom Study (RSS) is a multi-
center longitudinal study designed to assess the nature and determinants of RP symptoms in 
SSc. The present report focuses on the potential clinical associations of digital color changes 
of RP in SSc, self-management of SSc-RP symptoms, the presence of distinct patterns of 
SSc-RP and possible evolution of RP symptoms throughout the disease course. 
Patients and Methods: 
Patients 
 SSc patients fulfilling the 2013 ACR/EULAR classification criteria for SSc (6) were enrolled 
from SSc clinics held in Bath, UK and Salt Lake City, US at routine clinical care visits 
between April 2015 and January 2017.  The study had ethical approval at both sites and all 
participants provided informed written consent.  
Patient questionnaires 
Participants were issued with a pack containing the RSS questionnaire and a RCS diary. The 
first section of the RSS questionnaire focused on RP symptoms including digital colour 
changes, body parts affected, presence of numbness, non-thermal triggers and self-
management approaches (supplementary material available online). A history of white, blue, 
red and purple digital discolouration was captured in accordance with earlier work examining 
the specific self-reported digital colour changes used to diagnose/classify RP (7, 8)). Patients 
were subsequently classified as having uni-, bi-, tri- or quadri-phasic digital colour changes 
on the basis of the number of digital colour changes reported. Diagrammatic representations 
and descriptive stems of four theoretical SSc-RP patterns (A-D) were presented to the 
participants (Figure 1). These theoretical patterns of SSc-RP were developed using 
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experiences described by people with SSc and primary RP during instruction on completion 
of the RCS diary in an earlier study (16). It was during this work that many patients 
expressed difficulty completing the RCS diary because of difficulty differentiating RP attacks 
from background persistent digital ischaemia. The resulting images (and accompanying 
stems) were reviewed and refined with support from patient research partners affected by 
SSc-RP to ensure good comprehension. The 4 SSc-RP patterns describe symptoms of increasing 
severity (A through to D); with progressively greater amounts of time spent experiencing RP features 
(pain, numbness and discolouration) when symptomatic. Patterns C and D describe a symptom state 
in which the fingers feel cold with poor blood supply the majority of the time and rarely return to 
feeling normal (with difficulty identifying attacks of Raynaud’s from background digital ischaemia). 
Participants were presented with the images/stems and asked to indicate which pattern best 
described their SSc-RP symptoms currently and at the time their SSc-RP symptoms first 
emerged. SSc-RP symptom evolution over the disease course was further explored using 
direct questioning. Participants completed existing 100mm visual analogue scales (VAS) for 
patient global assessment , DU severity, SSc-RP severity alongside the Scleroderma Health 
Assessment Questionnaire (SHAQ) and its disease-specific 150mmVAS subscales (17). 
Patients were issued with the 2-week RCS diary alongside instructions for completion. 
Participants returned the completed questionnaire and RCS diary. The RCS diary was used to 
calculate the mean daily RCS (a 0-10 numeric rating scale assessing the overall 
impact/severity of RP symptoms on each day of diary collection), mean daily frequency of 
RP attacks and mean daily duration of RP attacks over the course of the 2-week RCS diary 
collection (10). Each of the RCS diary parameters were only calculated provided a minimum 
of 10 days (of 14) of the diary had been completed satisfactorily. 
Clinician case report form (CRF) 
A clinician CRF collected information on patient demographics (age, gender, ethnicity, 
disease duration based on time since 1st non-RP symptom), smoking history, clinical 
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phenotype and autoimmune serology. The clinical phenotype sought documented evidence 
from the case notes of gastro-esophageal reflux disease (GERD) symptoms, puffy fingers, 
sclerodactyly, digital ulcers (DU), digital pitting (DP), telangiectases, pulmonary arterial 
hypertension (PAH), interstitial lung disease (ILD) and autoantibody specificity; using 
definitions described in the 2013 ACR/EULAR classification criteria for SSc (6). Patients 
were sub-classified according to limited versus diffuse cutaneous SSc according to standard 
practice (18, 19). Relevant co-morbidities and vasoactive medication use were documented. 
Physicians completed 100mm VAS scores physician global assessment, RP severity and DU 
severity.  
Statistical analysis 
Descriptive statistics were applied and shall be defined were applicable. The Chi square test 
was used to compare observed frequencies across two or more categories. The unpaired t-test 
was used to compare distributions of continuous data when examining demographic data 
from the Bath and Utah cohorts. One way ANOVA or Kruskal-Wallis tests were applied to 
examine distribution of data across three or more independent samples as appropriate. 
Logistic regression models were used to compare observed frequencies across categories of 
digital colour changes, which are not mutually exclusive. This was an explorative study with 
multiple comparisons.  In an effort to avoid overlooking relevant signals, we chose not to 
apply a formal Bonferroni correction but we have been cautious in our interpretation of the 
significance of sporadic associations and only drawn conclusions where multiple 
comparisons lead to consistent positive associations. 
Results:  
One hundred and seven SSc patients were enrolled to the RSS (57 in Bath and 50 from Utah). 
Ninety-four  patients (82 female, 14 patients with diffuse cutaneous SSc) returned completed 
questionnaires. The patient demographics and clinical phenotype of the participants are 
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presented in Table 1. The clinical phenotype of the two cohorts were similar, although 
patients from Bath were older (65.1 vs. 56.4 years, p<0.001), had a higher age at diagnosis 
(54.6 vs. 47.3 years, p=0.02) and higher use of ACE inhibitors/Angiotensin II antagonists 
(p=0.02, Table 1). The reported prevalence of GERD (82% vs. 98%, p=0.01) and history of 
digital ulcer (DU, 43% vs. 68%, p=0.02) was higher in the Utah cohort. 
Digital color changes  
Virtually all patients reported digital color changes related to their SSc-RP (92/94, 98%). 
Digital color changes were typically related to cold exposure, although 47 patients (50%) 
reported color change or numbness at normal temperature in response to emotional stress. 
The individual fingers were affected equally (90%-98%) but there was relative sparing of the 
thumbs (58/94, 62%). Similarly, the toes (63/94, 67%), nose (26/94, 28%) and ears (18/94, 
19%) were less often affected by SSc-RP. No patients reported involvement of the nipples. 
The commonest reported digital color change was white (81/94, 86%), followed by purple 
(72/94, 77%), blue (69/94, 73%) and red (68/94, 72%). Over half of patients (48/94, 51%) 
reported quadri-phasic color changes, with smaller numbers reporting tri-phasic (20/94, 
21%), bi-phasic (14/94, 16%) and monophasic RP (only 10/94, 11%; the majority of whom 
reported isolated blanching [6/10]). A significant association was identified between the 
number of phases and the RCS with higher median “mean RCS score” for quadri-phasic RP 
(median 3.0 [inter-quartile range (IQR) 1.0-4.9]), compared to tri-phasic (1.7 [0.6-7.1]) and 
bi-phasic (0.5 [0.2-2.9]) SSc-RP symptoms (p=0.006). A similar relationship was identified 
for the number of digital color changes and both the median “mean frequency of attacks” 
(medians 2.1 [quadri-phasic], 1.5 [tri-phasic] and 0.3 [bi-phasic] respectively, p<0.001) and 
median “mean daily duration” of attacks (33.2, 12.3 and 5.4 respectively, p=0.008). There 
was no relationship between digital color changes and individual components of the SHAQ. 
The only associations between patient demographics/clinical phenotype and either individual 
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digital color changes reported or the number of reported digital color changes werean 
association between telangiectases and number of phases of RP (p=0.033) and the presence of 
sclerodactyly in patients reporting digital cyanosis (p=0.044].  These sporadic associations 
are likely to be the consequence of statistical issues concerning multiple testing and quasi-
complete separation respectively rather than clinically meaningful associations (data not 
reported).  
Self-management of SSc-RP 
Virtually all patients reported wearing layers of clothes to keep warm (89/94, 95%) and 
carrying gloves (81/94, 86%) to avoid attacks of SSc-RP. The majority of participants 
reported using hand warmers (67/94, 71%), seeking help from others (e.g. getting food from 
the fridge/freezer) (49, 52%) and avoiding going out when cold (65, 69%) as additional 
methods of avoiding SSc-RP symptoms. Many respondents reported using hand warmers 
(51/94, 54%) to ameliorate SSc-RP symptoms but a greater percentage reported submerging 
their hands in warm water (72/94, 77%). The majority of patients reported feeling better able 
to avoid SSc-RP attacks (48 [51%] participants agree/strongly agree vs. 22 [23%] 
disagree/strongly disagree) and shorten SSc-RP attacks (with 44 [47%] agree/strongly agree 
vs. 19 [20%] disagree/strongly disagree) over time.  
Patterns of SSc-RP 
Ninety-three (99%) of respondents could identify with a pattern of SSc-RP that corresponded 
to their current experience of SSc-RP. The majority of patients (44%) identified pattern B as 
being most representative of their current SSc-RP symptoms with 17% of subjects identifying 
with patterns C or D (Table 2). Ninety-two patients were able to identify with a pattern of 
SSc-RP that corresponded to their experience of SSc-RP at the time their symptoms first 
emerged (Table 2, Row 2). More patients identified with pattern A when their SSc-RP 
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symptoms first emerged than currently (50/92 vs. 36/93, p=0.04) and the observed 
frequencies within each pattern appears to have evolved over time (p=0.08, Table 2). Indeed, 
there was a strong signal to suggest greater disease duration in patients identifying with 
progressive SSc-RP patterns (p=0.05, Table 2). Overall, 28 patients (30%) reported 
advancement of the SSc-RP pattern over time; with 44 (48%) reporting a static pattern (this 
group also had a shorter mean disease duration) and 20 (22%) reporting an improvement in 
SSc-RP pattern. Participants reporting progression of the SSc-RP pattern were found to have 
higher RCS diary parameters (p<0.005) and a higher SHAQ RP VAS (p=0.001) than those 
whose SSc-RP remained static or improved (data not shown). 
Statistically significant associations were identified between reported SSc-RP patterns and 
conceptually-linked physician and patient assessments of peripheral vascular severity (e.g. 
physician RP VAS [p=0.007], SHAQ RP VAS [p<0.001] and the RCS diary parameters 
[p<0.005 for all], Table 2). Significant associations were also identified between SSc-RP 
patterns and both patient (p=0.002) and physician (p=0.02) global VAS assessments.  There 
was no association between SSc-RP patterns and conceptually unrelated outcomes such as the 
SHAQ breathing VAS (p=0.27, Table 2), although associations were found with the SSc-RP 
patterns and the SHAQ GI VAS scores.  
Evolution of SSc-RP symptoms over time 
The cohort was evenly split with respect to whether SSc-RP symptoms had evolved over the 
course of the disease. Thirty-six participants (38%) reported worsening of their SSc-RP over 
time, whereas 22 (23%) felt there had been an overall improvement, with the remaining 36 
(38%) patients reporting their symptoms as stable (or undecided). Most participants (43/94, 
46%) reported an increase in the frequency of SSc-RP episodes, whereas 20 (21%) 
respondents felt they had become less frequent and the remaining 31 (33%) felt the frequency 
was unchanged (or undecided). Similarly, the duration/length of SSc-RP episodes was 
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reported as increased in 39 (41%), decreased in 20 (21%) and unchanged in the remaining 35 
(37%) participants.  A similar distribution was found for evolving severity of SSc-RP 
episodes (36 [38%] worse, 20 [21%] better and 38 [40%] the same). Consistent with the 
aforementioned patterns of RP, a significant number of participants (21, 22%) reported 
finding it harder to distinguish SSc-RP attacks from background digital ischemia. The 
majority of patients (35, 37%) were undecided whether or not their SSc-RP medications were 
working better as their disease advanced. Thirty (32%) of respondents agreed/strongly agreed 
that their SSc-RP medications had become more effective over time whereas 14 (15%) 
disagreed/strongly disagreed with this statement [data missing on 15 subjects]. The choice 
and availability of new treatments (e.g. phosphodiesterase inhibitors) makes it difficult to 
fully understand the relationship between SSc-RP symptom burden and medication use.  
Discussion 
We report the findings of a large study investigating the nature and evolution of RP 
symptoms in SSc. The apparent evolution of RP symptoms, characterised by more persistent 
symptoms of digital ischemia, could reflect progression of the obliterative microangiopathy 
of SSc. These findings shed light on possible determinants of SSc-RP and have implications 
for future RP management and clinical trial design. 
In contrast with earlier work (9), monophasic RP was only reported in 11% of our SSc 
patients although this could still have implications for disease classification in early SSc 
when disproportionate weighting is attached to achieving definitions for RP (“two-phase 
colour change in fingers”) given other organ manifestations may have yet to emerge (6). Our 
prevalent cohort study design does not allow examination of digital colour changes at 
diagnosis, which may differ from that of established disease considering our findings 
supporting SSc-RP symptom evolution. A higher number of reported digital colour changes 
was associated with higher overall SSc-RP severity assessed using the RCS diary parameters 
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but we did not identify any differences in clinical phenotype associated with specific patient-
reported digital colour changes of SSc-RP (or combinations thereof) suggesting repeated 
enquiry is of limited value in the clinical setting. We were surprised by the lack of association 
between digital colour changes and clinical outcomes (having hypothesized that cyanosis 
[blue and/or purple] might be a marker of more severe digital vasculopathy). We undertook 
an extensive review of each of the digital colour changes (and combinations thereof) but did 
not identify any meaningful associations. One explanation for this might be the high 
prevalence of all the digital colour changes (72-86%) across the group making it difficult to 
identify clinical associations. It is possible that the use of colour charts or clinician-observed 
digital colour changes might be more effective than self-report at identifying clinical 
associations with specific digital colour changes of SSc-RP.” 
We explored self-management approaches taken by patients to avoid or ameliorate symptoms 
of SSc-RP and our analysis suggests the majority of patients feel better able to manage their 
symptoms over time, supporting the findings of previous qualitative research that identified 
successful adaptation as an important determinant of the overall burden of SSc-RP (4). For 
the first time, we have shown that SSc patients identify with different patterns of SSc-RP. 
The apparent evolution in SSc-RP pattern since symptom onset and association between 
worsening RP pattern and disease duration is suggestive of a possible relationship with the 
progressive obliterative microangiopathy of SSc, although additional work exploring the 
relationship between patterns of SSc-RP and capillary morphology at the nail fold would 
strengthen this supposition. Worsening SSc-RP patterns were associated with physician and 
patient assessments of global disease burden and peripheral vascular severity. This included 
assessment of RP severity using RCS diary parameters. We had hypothesised that more 
persistent symptoms of digital ischaemia may translate into the reporting of fewer SSc-RP 
attacks (with major implications for current SSc-RP trial design and interpretation) but our 
data did not support this. This does not negate the potential importance of different patterns 
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of SSc-RP with respect to treatment outcomes and clinical trial design, which should form the 
focus of further research. Indeed, over 20% of patients reported difficulty distinguishing 
discrete attacks of SSc-RP from background digital ischemia, which might have an important 
influence on diary-based approaches to RP assessment. There was no relationship between 
SSc-RP patterns and the conceptually-unrelated SHAQ breathing VAS but a surprising 
relationship was identified with the SHAQ GI VAS. This might reflect a true association 
between GI disease and peripheral vascular dysfunction in SSc. Alternatively, the 
relationship may reflect shared experiences around pain with both RP and GI disturbance (but 
not breathlessness) in SSc. These observations could form the focus of further research. 
The cohort was relatively evenly split when asked whether their SSc-RP symptoms have 
worsened (~35%), remained the same (~35%) or improved (~20%) over time. A number of 
factors might contribute to these findings including progression (or regression) of peripheral 
microangiopathy, treatment efficacy, self-efficacy, habituation and adaptation (20).  
This study benefits from being a comparatively large multi-centre study of SSc but the 
questionnaire design limits the extent to which we can explore the potential mechanisms 
underpinning SSc-RP symptom characteristics and symptom burden. Future longitudinal 
studies incorporating microvascular imaging shall help further elucidate determinants of RP 
symptom evolution in SSc and the implications for management.  
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Figure 1. Diagrammatic representations and descriptive stems for four theoretical 
patterns of Raynaud’s phenomenon 
 
The four labelled images represent theoretical patterns of Raynaud’s symptoms. Participants 
were asked to consider which image and stem best described their experience of Raynaud’s 
phenomenon. The dotted line indicates the threshold at which they might experience 
symptoms of Raynaud’s phenomenon. Each image was accompanied by the following 
statements to aid participants when making their choice: 
A) Intermittent short-lasting attacks of Raynaud’s with the circulation in the fingers always 
returning to normal in between attacks (the fingers feel warm to touch with good blood 
supply the majority of the time). 
B) Intermittent longer-lasting attacks of Raynaud’s with the circulation in the fingers not 
always returning completely back to normal (warm and pink) in between attacks. My fingers 
feel cold and appear discoloured as often as they feel normal. 
C) Intermittent attacks of acute Raynaud’s but the fingers feel cold with poor blood supply 
the majority of the time and rarely return to feeling normal. It can be difficult to identify 
actual attacks of Raynaud’s from how they feel constantly.  
D) The fingers are cold and discoloured all of the time and I find almost impossible to 
appreciate distinct attacks of Raynaud’s as the blood supply to the fingers appears to be 
permanently reduced.  
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Table 1. Patient demographics and clinical phenotype of participants. 
* comparing Bath with SLC using unpaired t test or Chi square as appropriate 
¥ We are unable to attribute the chief indicator for individual vasodilator medication which 
may include SSc-RP, digital ulcer disease, pulmonary arterial hypertension and conventional 
cardiovascular disease. 
 All  Bath  SLC P value* 
Number of patients  94 44 50 N/A 
Age in years, mean (SD)  60.5 (11.9) 65.1 (9.1) 56.4 (12.7) <0.001 
Age at diagnosis, mean (SD) 50.6 (14.9) 54.6 (12.8) 47.3 (16.2) 0.02 
Disease duration, mean (SD) 9.9 (9.1) 10.6 (9.8) 9.2 (8.7) 0.45 
Time from RP to 1st non RP 
symptom, mean (SD) 
4.9 (9.4) 6.5 (9.2) 3.6 (9.5) 0.14 
Female, n (%) 82 (87) 40 (91) 42 (84) 0.37 
Male, n (%) 12 (13) 4 (9) 8 (16) 
Limited cutaneous SSc, n (%) 78 (83) 38 (86) 40 (80) 0.67 
Diffuse cutaneous SSc, n (%) 14 (15) 5 (12) 9 (18) 
SSc sine scleroderma, n (%) 2  (2) 1 (2) 1 (2) 
Raynaud’s, n (%) 94 (100) 44 (100) 50 (100) 1.00 
GERD, n (%) 85 (90) 36 (82) 49 (98) 0.01 
Sclerodactyly, n (%) 79 (84) 36 (82) 43 (86) 0.78 
History of digital ulcers, n (%) 53 (56) 19 (43) 34 (68) 0.02 
Telangiectasia, n (%) 80 (85) 37 (84) 43 (86) 1.00 
Pulmonary hypertension, n (%) 17 (18) 7 (16) 10 (20) 0.79 
Interstitial lung disease, n (%) 34 (36) 13 (30) 21 (42) 0.28 
Caucasian, n (%) 88 (94) 42 (95) 46 (92) 0.68 
Current smoker, n (%) 8 (9) 3 (7) 5 (10) 0.72 
Ex-smoker, n (%) 23 (25) 12 (27) 11 (22) 
Never smoker, n (%) 61 (65) 27 (61) 34 (68) 
Antibody profile (not all mutually exclusive) 
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Anticentromere, n (%) 47 (50) 25 (57) 22 (44) 0.18 
Anti-Scl 70, n (%) 13 (1) 7 (16) 6 (12) 
Anti-U1-RNP, n (%) 11 (11) 3 (7) 8 (16) 
Anti- RNA Pol III, n (%) 9 (9) 2 (5) 7 (14) 
Anti-Th/To 4 (4) 3 (7) 1 (2)  
Anti-Ro 60 7 (7) 6 (14) 1 (2)  
Anti-R0 52 1 (1) 1 (2) 0  
Anti-PM-Scl 3 (3) 0 (0) 3 (6)  
Anti-U3-RNP 1 (1) 0 (0) 1 (2)  
Vasodilator medication ¥ 
Calcium channel antagonists 51 (54) 18 (41) 33 (66) 0.03 ǂ 
ACE inhibitors / Angiotensin II 
antagonists ǂ p=0.02 for this 
medication class 
18 (19.1) 13 (30) 5 (10) 
PDE5 inhibitors 15 (16) 9 (20) 6 (12) 
ERA 7 (7) 4 (9) 3 (6) 
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Table 2. The relationship between physician and patient assessments of disease severity 
and SSc-RP patterns identified by participants 
All values mean (SD) unless stated. *one way ANOVA or Chi squared as appropriate. 
SSc, Systemic sclerosis; RP, Raynaud’s phenomenon; VAS, visual analogue scale; HAQ-DI, 
Health Assessment Questionnaire-Disability Index; GI, Gastrointestinal; DU, digital ulcer; 
RCS, Raynaud’s Condition Score; 
 Pattern A  Pattern B  Pattern C  Pattern D  p value *  
Current SSc-RP pattern, 
n (%) 
36 (39) 41 (44) 13 (14) 3 (3) 0.08 
Initial SSc-RP pattern, 
n (%) 
50 (54) 25 (27) 12 (13) 5 (3) 
Disease duration, years 8.5 (9.9) 9.0 (8.3) 15 (8.23) 18 (1.73) 0.05 
Physician and patient 100mm VAS scores 
Physician RP VAS (0-
100) 
20.5 (19.1) 30.9 (21.9) 33.9 (25.9) 61 (35.9) 0.007 
Physician global VAS 
(0-100) 
24.5 (22.0) 32.8 (25.6) 37.7 (25.2) 68.3 (28.4) 0.02 
Patient global VAS (0-
100) 
28.3 (25.1) 43.8 (23.2) 49.2 (32.6) 76.7 (12.4) 0.002 
Scleroderma Health Assessment Questionnaire (SHAQ) indices 
HAQ-DI (0-3.0) 0.5 (0.5) 1.0 (0.7) 1.3 (0.8) 1.9 (0.5) <0.001 
Pain VAS (0-3.0) 0.7 (0.8) 1.2 (0.9) 1.6 (0.9) 2.3 (0.3) <0.001 
GI VAS (0-3.0) 0.5 (0.6) 0.8 (0.8) 1.5 (1.2) 2.6 (0.5) <0.001 
Breathing VAS (0-3.0) 0.5 (0.6) 0.8 (0.8) 0.8 (0.9) 1.2 (1.1) 0.27 
RP VAS (0-3.0)  0.3 (0.6) 0.9 (0.8) 1.1 (0.9) 2.8 (0.2) <0.001 
DU VAS (0-3.0)  0.2 (0.5) 0.5 (0.8) 0.9 (1.2) 1.5 (1.5) 0.007 
Global VAS (0-3.0) 0.6 (0.7) 1.3 (0.8) 1.5 (1.1) 2.7 (0.2) <0.001 
RCS diary parameters 
Mean daily RCS score 
(0-10)  
1.6 (1.8) 3.5 (2.5) 4.0 (2.4) 5.4 (2.1) <0.001 
Mean daily RP 
frequency (per day) 
1.1 (1.1) 2.3 (1.7) 3.6 (1.9) 4.4 (4.4) <0.001 
Mean daily RP duration 
(mins) 
17.4 (22.8) 66.6 (80.7) 94.9 (103.1) 125.1 
(114.3) 
0.002 
 
